TY - JOUR
T1 - Early-onset diffuse gastric cancer associated with a de novo large genomic deletion of CDH1 gene
AU - Sugimoto, Shinya
AU - Yamada, Hidetaka
AU - Takahashi, Masazumi
AU - Morohoshi, Yuichi
AU - Yamaguchi, Naotaka
AU - Tsunoda, Yuya
AU - Hayashi, Hiroyuki
AU - Sugimura, Haruhiko
AU - Komatsu, Hirokazu
N1 - Funding Information:
This work was supported by grants from the Ministry of Health, Labour and Welfare (10103838), Ministry of Education, Culture, Sports, Science and Technology (S-001), National Cancer Center Research and Development Fund, Princess Takamatsu Cancer Research Fund, and the Smoking Research Foundation.
Publisher Copyright:
© 2013, The Author(s).
PY - 2014/9/20
Y1 - 2014/9/20
N2 - A 41-year-old man with no familial history of gastric cancer was diagnosed as with intramucosal early gastric cancer. Two months after the first endoscopic submucosal dissection for signet-ring cell carcinoma (SRCC), the appearance of previously unrecognized multiple erosions of SRCC was noticed. Pathological examination after a total gastrectomy and Roux-en-Y reconstruction with D2 lymph node dissection were performed. Postoperative pathological examination revealed 90 and more lesions, which tempted the attending pathologist to refer to genetic tests for the predisposition though the patient had no familial history of gastric cancer. There were no mutations in all the exons of CDH1 with conventional DNA sequencing, but multiplex ligation-dependent probe amplification, and reverse transcription-polymerase chain reaction analyses disclosed a large genomic deletion (c.1566-?_1711+?del), leading to the mRNA with loss of the exon 11. Among family members, his son was found to be a carrier of this change, while his parents were negative for the familial CDH1 mutation, implying that this change is a de novo event in the proband. The present report is the first description of a de novo large genomic deletion of CDH1 gene associated with early-onset diffuse gastric cancer. When the clinician finds a relatively-young patient who has multiple SRCCs, CDH1 germline mutation should be considered, even for patients with no familial history.
AB - A 41-year-old man with no familial history of gastric cancer was diagnosed as with intramucosal early gastric cancer. Two months after the first endoscopic submucosal dissection for signet-ring cell carcinoma (SRCC), the appearance of previously unrecognized multiple erosions of SRCC was noticed. Pathological examination after a total gastrectomy and Roux-en-Y reconstruction with D2 lymph node dissection were performed. Postoperative pathological examination revealed 90 and more lesions, which tempted the attending pathologist to refer to genetic tests for the predisposition though the patient had no familial history of gastric cancer. There were no mutations in all the exons of CDH1 with conventional DNA sequencing, but multiplex ligation-dependent probe amplification, and reverse transcription-polymerase chain reaction analyses disclosed a large genomic deletion (c.1566-?_1711+?del), leading to the mRNA with loss of the exon 11. Among family members, his son was found to be a carrier of this change, while his parents were negative for the familial CDH1 mutation, implying that this change is a de novo event in the proband. The present report is the first description of a de novo large genomic deletion of CDH1 gene associated with early-onset diffuse gastric cancer. When the clinician finds a relatively-young patient who has multiple SRCCs, CDH1 germline mutation should be considered, even for patients with no familial history.
KW - CDH1
KW - Endoscopic submucosal dissection
KW - Mutation
KW - Signet-ring cell carcinoma
KW - Stomach neoplasms
UR - http://www.scopus.com/inward/record.url?scp=84919391016&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84919391016&partnerID=8YFLogxK
U2 - 10.1007/s10120-013-0278-2
DO - 10.1007/s10120-013-0278-2
M3 - Article
C2 - 23812922
AN - SCOPUS:84919391016
SN - 1436-3291
VL - 17
SP - 745
EP - 749
JO - Gastric Cancer
JF - Gastric Cancer
IS - 4
ER -